Get the Daily Brief
Latest Biotech News
10x Genomics pushes diagnostics: clinical collaborations and CLIA lab plans
10x Genomics announced three clinically focused collaborations and plans to open a CLIA‑certified lab in early 2027 as it seeks to translate single‑cell and spatial platforms into diagnostic...
Targeted delivery and IND green light: Tessera cleared for in vivo gene‑editing trial
Tessera Therapeutics received FDA clearance to begin a Phase I/II clinical trial of TSRA‑196, its in‑vivo gene‑editing candidate for alpha‑1 antitrypsin deficiency, and received HREC approval in...
Big‑ticket oncology licensing: AbbVie and Novartis make strategic bets
AbbVie agreed to pay $650 million up front to license RemeGen’s PD‑1×VEGF bispecific antibody outside greater China, entering a crowded bispecific oncology field with milestone potential into the...
Data and diagnostics integration: ConcertAI adds Foundation Medicine; MeMed wins biobank grant
ConcertAI and Foundation Medicine struck a data collaboration to merge Foundation Medicine’s de‑identified genomic and multimodal data with ConcertAI’s clinically linked datasets, creating a...
AbbVie bets big on PD‑1xVEGF: $650M upfront with RemeGen
AbbVie struck a major oncology pact with China’s RemeGen, paying $650 million upfront to license a PD‑1xVEGF bispecific program. The deal formalizes AbbVie’s entry into a crowded bispecific field...
Novartis buys a brain‑shuttle ticket: $165M deal with SciNeuro
Novartis licensed a preclinical amyloid‑targeting shuttle program from SciNeuro, paying $165 million upfront with up to $1.5 billion in downstream milestones. The collaboration aims to use...
Eli Lilly, Nvidia ink AI lab pact: five years, up to $1B
Eli Lilly signed a multi‑year collaboration with Nvidia to build an AI laboratory for drug discovery and development, committing up to $1 billion over five years. The partnership will combine...
Oxford Nanopore clears CE/UKCA for GridIon Dx — clinical push begins
Oxford Nanopore received CE‑IVDR and UKCA marks for its GridIon Dx sequencer, its first IVD‑marked device in Europe and the U.K., and signaled initial clinical use through a BioMérieux partnership...
Tessera clears IND — in vivo gene editing enters clinic for AATD
The U.S. FDA cleared Tessera’s IND for TSRA‑196, its in vivo gene‑editing candidate for alpha‑1 antitrypsin deficiency, and Australia’s HREC approved the phase I/II study there. The green light...
Parabilis raises $305M to push desmoid tumor program into Phase III
Parabilis Medicines closed a $305 million Series F to advance zolucatetide (FOG‑001) toward Phase III for desmoid tumors and to support broader development. The financing was led by RA Capital,...
Mirador raises $250M — building an immunology powerhouse
Mirador Therapeutics closed a $250 million Series B to expand its precision immunology pipeline and signaled intentions to scale toward an IPO later this year. The financing will fund clinical and...
MRD and oncology testing surge: Natera and Adaptive post sharp revenue gains
Natera reported a roughly 39% jump in preliminary Q4 revenue driven by Signatera MRD test volume, processing 225,300 MRD tests in the quarter and forecasting $2.3 billion revenue for 2025....
Testing boom fuels Tempus and Guardant revenue leaps
Tempus reported preliminary Q4 revenue up ~83% year‑over‑year and full‑year 2025 revenue of about $1.27 billion, driven by diagnostics and data licensing deals. Guardant Health said preliminary Q4...
Eikon files for IPO — protein‑movement platform goes public push
Eikon Therapeutics, the high‑profile startup built around protein dynamics technology and led by former Merck executives, filed to go public as it looks to bankroll a clutch of clinical cancer and...
In vivo genome editing: delivery breakthroughs accelerate clinical translation
Researchers and commentators reported new advances in delivering genome editors directly to tissues in living organisms. Doudna and colleagues framed a rational design approach for targeted...
Novartis licenses SciNeuro amyloid program: $165 million upfront
Novartis agreed to license a preclinical amyloid-targeting Alzheimer’s program from SciNeuro with a $165 million upfront payment and a joint early-development plan. The deal gives Novartis rights...
FDA rejects Atara’s EBV cell therapy — regulator stalls approval again
The FDA issued another rejection of Atara Biotherapeutics’ tabelecleucel (tab-cel), a T cell therapy for Epstein-Barr virus (EBV)-related complications after transplantation. The agency’s decision...
Parabilis raises $305M: funds Phase III push for desmoid tumor candidate
Parabilis Medicines closed a $305 million Series F financing led by RA Capital, Fidelity and Janus Henderson to advance zolucatetide (FOG-001) toward Phase III for desmoid tumors. The company said...
Kinaset bags $103M Series B to advance inhaled asthma program
Kinaset Therapeutics secured $103 million in a Series B round to progress its inhaled candidate for asthma toward late-stage testing. The financing comes five years after the company’s initial...
Mirador nets $250M — builds immunology platform and eyes IPO
Mirador Therapeutics closed a $250 million Series B to accelerate its precision-immunology pipeline and signaled plans to consider an IPO later in the year. The financing will support clinical...